Project Grant R01HL181346
Award Date 9/10/25
Completion Date 6/30/30
Dollars Obligated $644K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- This $713,511 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the impact of myosin-binding protein C (MyBP-C) on myosin mobility and proteostasis in the context of hypertrophic cardiomyopathy (HCM). The University of Vermont & State Agricultural College, the awardee, will utilize innovative techniques to investigate how reduced MyBP-C levels, a common cause of HCM, may disrupt normal heart...
- This Project Grant award of $634,183, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at Loyola University of Chicago's Health Sciences Campus to investigate the molecular mechanisms of cardiac ryanodine receptor (RyR) dysfunction during oxidative stress and myocardial infarction. The primary goal is to define how oxidative stress-induced intersubunit cross-linking of RyR impacts calcium homeostasis and...
- The National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $776,791 Project Grant to The Washington University to study the impact of sequence changes on key intrinsically disordered regions of cardiac troponin. This research aims to elucidate how mutations and post-translational modifications affecting disordered regions of the troponin complex can disrupt cardiac muscle contraction regulation, leading to diseases like...
- This Project Grant award, funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), totaling $589,998 over the period of September 1, 2025 to August 31, 2028, will support research to investigate cardiac sensory and sympathetic nerve dysregulation in hypertrophic cardiomyopathy (HCM). The project aims to test the hypothesis that HCM leads to increased chemosensitivity in cardiac spinal afferents, contributing to cardiovascular instability,...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), funds a study to investigate the molecular mechanisms linking atrial cardiopathy to cardiovascular disease outcomes. The $1,657,473 award, granted on September 24, 2025, supports the use of proteomic and genomic methods in two diverse populations - individuals free of clinically recognized cardiovascular disease and patients with recent...
- This Project Grant award of $673,642.00 was provided by the National Heart Lung and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) to study the role of lysosomes in arrhythmia and sudden cardiac death. The principal investigator will investigate whether cardiac lysosomes, similar to mitochondria, can contribute to arrhythmic risk during cardiomyopathy by releasing calcium and triggering calcium sparks in the sarcoplasmic reticulum. The project aims to elucidate the specific...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
- This Project Grant award of $231,000.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), to study the functional impact of atrial myosin mutations associated with familial atrial arrhythmia. The research aims to comprehensively analyze the effects of known genetic mutations in the a-cardiac myosin heavy chain, essential light chain, and regulatory light chain on myosin activity and sarcomere...
- This Project Grant award of $167,400 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Dr. Joshua Meisner at the University of Michigan to elucidate the mechanical and metabolic pathways underlying MYBPC3 hypertrophic cardiomyopathy. The research aims to develop novel in vivo and in vitro models to study the progression of this severe, adolescent-onset heart disease, and test the reversibility of pathology by targeting...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $425,505 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Louisiana State University Health Sciences Center-Shreveport (LSU Health Sciences Center-Shreveport) to investigate the role of cell-specific Programmed Death-Ligand 1 (PD-L1) in cardiac pathophysiology following ischemic injury and cancer. The project aims to elucidate the specific mechanisms by which fibroblast-specific and myeloid...